STK33 Promotes Growth and Progression of Pancreatic Cancer as a Critical Downstream Mediator of HIF1α.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29038348.
- Also identified by DOI 10.1158/0008-5472.CAN-17-0067.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The serine/threonine kinase STK33 has been implicated in cancer cell proliferation. Here, we provide evidence of a critical role for STK33 in the pathogenesis and metastatic progression of pancreatic ductal adenocarcinoma (PDAC). STK33 expression in PDAC was regulated by the hypoxia-inducible transcription factor HIF1α. In human PDAC specimens, STK33 was overexpressed and associated with poor prognosis. Enforced STK33 expression promoted PDAC proliferation, migration, invasion, and tumor growth, whereas STK33 depletion exerted opposing effects. Mechanistic investigations showed that HIF1α regulated STK33 via direct binding to a hypoxia response element in its promoter. In showing that dysregulated HIF1α/STK33 signaling promotes PDAC growth and progression, our results suggest STK33 as a candidate therapeutic target to improve PDAC treatment. <i>Cancer Res; 77(24); 6851-62. ©2017 AACR</i>.
Medical subject headings
- Carcinoma, Pancreatic Ductal
- Cell Proliferation
- Hypoxia-Inducible Factor 1, alpha Subunit
- Pancreatic Neoplasms
- Protein Serine-Threonine Kinases